Skip to main content
Science & Medicine· Explainer

The Vape Said Cannabis. The Withdrawal Said Opioid.

Five young men in Sydney landed in severe opioid withdrawal from vapes they thought held THC or nicotine. The culprit was a nitazene. Here's what that means on this side of the Pacific.

ByThe Rize NewsroomNovember 16, 20266 min readNovel & Emerging Psychoactives

They were six young men in metropolitan Sydney, five of them from multicultural backgrounds. Five of them vaped regularly, and each believed he knew what was in the device: a cannabis product, or nicotine. Then they got sick in a way that made no sense for either, the particular sickness of a body that has had an opioid taken away. When they landed at a public hospital, the doctors were looking at severe opioid withdrawal in young men who thought they had been vaping weed or nicotine. The toxicology, delayed, eventually named the culprit: protonitazene, a synthetic opioid in the same family as some of the most potent street drugs ever found. (The sixth man had used a different nitazene on purpose.)

The case series, posted this weekend in Drug and Alcohol Review, is six patients long. Its warning is bigger than that.

If a vape can carry an opioid you didn’t choose, “I only smoke weed” is no longer a safety plan.

What a nitazene is, and why your body doesn’t care that you didn’t know

Nitazenes are a family of lab-made opioids first synthesized as painkillers in the 1950s and never approved for medical use. Like heroin and fentanyl, they lock onto the brain’s opioid receptors, the switches that control pain, pleasure and breathing. Some of them are far stronger than fentanyl; reporting by Bellingcat and STAT this summer put the most potent ones at up to 40 times stronger than fentanyl. Because they are so strong, a dealer needs only a speck, which makes them easy to ship and easy to slip into something else.

Here’s the biology that matters for the Sydney patients. Dependence is not a moral event; it’s an adaptation. When opioid receptors get hit every day, the brain turns down its own response to keep balance, and it starts to need the drug just to feel normal. Stop, and the system swings the other way: the body that was being slowed down is suddenly running too fast. That’s withdrawal. It does not matter whether you meant to take an opioid. Your receptors only know what reached them. A person who vapes all day, every day, the way plenty of people vape nicotine or THC, is dosing more often than most people who use heroin. With a nitazene in the cartridge, that’s a fast road to physical dependence.

It also explains the psychology of what these patients went through, which is its own kind of harm. Imagine being told you have an opioid problem when, as far as you knew, you were using a legal-adjacent product your friends used. The authors list “initial diagnostic confusion” among the complications, and two of the six patients were eventually lost to follow-up. That’s not surprising. It is hard to accept treatment for a condition you don’t believe you have, and harder still when the confirming lab result takes a while to come back.

Treatment worked, but it took more than usual

The good news in the paper is direct: all six patients were treated with the standard medicines for opioid dependence, methadone or buprenorphine, four as inpatients and two as outpatients, and four stayed in care. The authors note that “high doses of buprenorphine were required,” similar to what clinicians see with fentanyl. Buprenorphine is a partial opioid that holds the receptors steady and blocks stronger opioids from landing; with very potent drugs, it can take more of it to get a person comfortable. That is a six-patient observation, not a dosing guideline, and the paper doesn’t publish the doses. But it’s consistent with what clinicians have reported with fentanyl and it’s useful to know.

Overdose is the other half of the story. Naloxone (Narcan) still works on nitazenes because they are opioids. But a small 2023 emergency-department study in JAMA Network Open, led by Alexandra Amaducci, found patients overdosing on novel potent opioids, mostly nitazenes, received an average of 1.33 naloxone doses versus 0.36 for fentanyl-only patients. The comparison involved only about 20 patients, so treat it as a warning sign, not a rule. The practical takeaway is the same one harm reduction workers already give: carry more than one dose, call 911, and keep giving breaths while you wait.

The practical takeaway is the same one harm reduction workers already give: carry more than one dose, call 911, and keep giving breaths while you wait.

We’ve watched vapes carry hidden poison before

This would not be the first time the black-market vape cartridge became a delivery system for something nobody signed up for. In the summer of 2019, young people across the United States started showing up in emergency rooms with lungs that looked burned from the inside. By February 2020, the CDC had counted 2,807 hospitalized cases or deaths from what it named EVALI, and lab work tied the outbreak to vitamin E acetate, a thickener added to illicit THC cartridges to stretch them. The people hurt weren’t doing anything unusual. They bought a cartridge that looked like every other cartridge. What made it deadly was invisible and added somewhere upstream, for profit. Nitazene vapes follow the same pattern, with a far more dangerous additive: an unregulated product, a cheap and potent ingredient, and a user who has no way to see inside the device.

What this means in the U.S. right now

We found no confirmed reports of nitazene-laced vapes in the United States in the reporting we reviewed, and that’s worth saying plainly so nobody panics. But the ingredients for it are here. Confirmed U.S. deaths involving nitazenes climbed from 27 in 2020 to 409 in 2024, and nitazenes have been seized in 48 of 50 states, according to the CDC and DEA figures compiled by STAT. Alex Krotulski of the Center for Forensic Science Research and Education told the outlet, “There are only limited forensic toxicology labs that test for nitazenes,” which means many cases are likely never counted. And Australia keeps finding them in places they shouldn’t be: in November, Victoria’s forensic medicine institute reported a nitazene in a purple liquid sold as oxycodone, with no oxycodone in it at all.

If you vape THC or nicotine from an unlicensed shop, a friend, or online, here is what to know. If stopping makes you feel like you have the flu, with yawning, runny nose, goosebumps, sweating, aches, diarrhea or intense cravings, that pattern looks like opioid withdrawal, and you should tell a doctor exactly what you’ve been vaping and where you got it. Opioid withdrawal is treatable, and the medicines that treat it work for nitazenes too. Keep naloxone around, even if you’ve never touched an opioid on purpose.

For clinicians, the do-this-week move: when a young patient presents in opioid withdrawal and denies opioid use, ask about vapes by brand and source before you decide they’re not telling you the truth. Standard urine screens and fentanyl tests often won’t catch nitazenes, so ask your lab whether it can send out an expanded panel. Be ready to start buprenorphine at higher doses than you’d expect.

We’ve been covering nitazenes since they started spreading in the U.S. and the sedative medetomidine, which changed withdrawal care this year. You can follow all of it on our novel and emerging substances page and in Science & Medicine.

Five young men in Sydney did everything they thought counted as playing it safe. They stuck to what they knew. The supply decided otherwise. The least we owe the next person is a doctor who asks the right question the first time.

Filed Under

sciencebiologyharm-reductionNitazenesVapingSynthetic CannabinoidsYouth & Young AdultsMAT — BuprenorphineNaloxonePeer-Reviewed ResearchResearch Chemicals

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section